-
Ferring Pharmaceuticals appoints Alex Chang Senior Vice President, Asia Pacific
in PRESS RELEASE 2013 onFerring Pharmaceuticals announced today that it has appointed Alex Chang to head the company’s Asia Pacific region effective 1 November 2013…
-
MISODEL™, Ferring’s removable misoprostol vaginal delivery system, approved for labour induction in European Decentralised Procedure
in PRESS RELEASE 2013 onFerring Pharmaceuticals announced today that its MISODELTM (misoprostol) removable, controlled-release vaginal delivery system for labour induction…
-
Ferring announces second $3 million donation to the Royal Textile Academy of Bhutan
in PRESS RELEASE 2013 onFerring Pharmaceuticals has announced a second $3 million donation to the Royal Textile Academy of Bhutan to support its mission to preserve and…
-
Ferring presents phase III data for a controlled release misoprostol vaginal delivery system for labour induction at the First European Congress on Intrapartum Care
in PRESS RELEASE 2013 onData from the EXPEDITE study presented today at the First European Congress on Intrapartum Care (ECIC) demonstrated…
-
Ferring Pharmaceuticals begins phase III trials of elobixibat, new compound with novel mechanism of action for chronic idiopathic constipation
in PRESS RELEASE 2013 onFerring Pharmaceuticals today announced it has initiated enrolment of patients in two phase III clinical trials…
-
Ferring to Present Safety Analysis for FIRMAGON® (degarelix) at the American Urological Association Annual Meeting
in PRESS RELEASE 2013 onThe following data will be presented at the annual meeting of the American Urological Association (AUA) in San Diego…
-
New data highlight considerable burden of Nocturia
in PRESS RELEASE 2013 onNew data presented today at the European Association of Urology (EAU) congress show that nocturia (waking up one or more times to void at night)…
-
Data suggest lower risk of cardiovascular events or deaths in prostate cancer patients treated with degarelix compared to LHRH agonists
in PRESS RELEASE 2013 onData presented today at the European Association of Urology (EAU) 2013 annual meeting in Milan, indicate that the gonadotropin releasing hormone…
-
In patients with active, left-sided ulcerative colitis, study shows once-daily dose of mesalazine granules provided similar results to twice-daily dose
in PRESS RELEASE 2013 onResults of a recent sub analysis1 of data from the MOTUS study2 presented today at the Congress of European Crohn’s and Colitis Organisation…
PRESS RELEASE 2013
PRESS RELEASE 2013
